Research Supports FDA Label Update for Echocardiogram Agent | MedStar Health
Research Supports FDA Label Update for Echocardiogram Agent
Monday, January 02, 2017

Neil Weissman, MD, commented on the U.S. Food and Drug Administration (FDA) approval of an important label update for an echocardiogram contrast agent. “This is particularly noteworthy as DEFINITY is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings,” said Dr. Weissman. Read more.
Categories
Media Contact
Katie Carlin
Sr. Director, Business Development and Planning
410-772-6796katie.n.carlin@medstar.net
Browse by Category
- View all categories
- Ambulatory
- Awards and Accreditation
- Cancer
- Cardiology
- Community Health
- Compliance
- COVID-19
- Diabetes
- Education
- Emergency
- Focus Blog
- Geriatrics
- Hand
- Healthcare Industry
- Healthcare Quality Improvement
- Heart and Vascular
- Innovation
- Medical Education
- MedStar Health in the Community
- MedStar Health System News
- MedStar Institute for Innovation
- MedStar Institute for Quality and Safety
- Neurosciences
- Nursing
- Orthopaedics and Sports Medicine
- Pediatrics
- Philanthropy
- Physical Therapy
- Primary Care
- Pulmonology
- Quality and Patient Safety
- Radiology
- Rehabilitation
- Research
- Transplant
- Urgent Care
- Urology
- Wellbeing
- Women’s services